International Journal of Sciences: Basic and Applied Research
Abstract
We aimed to evaluate the long-term follow-up results of patients with prostate cancer implanted with ultrasound-guided fiducial marker(FM). Forty patients, between 2012-2017 were evaluated. Firstly, the gastrointestinal-genitourinary system side effects were questioned twice immediately after FM implant and in the median 6.5th year and the grading was performed via the NCI CTCAE-V5.0 test and compared. Secondly, in the late period, questions assessing genitourinary-gastrointestinal symptoms were asked using the EORTC QLQ-PR25 Module,and the complication status and patient comfort were assessed The mean symptom value for all patients in the EORTC QLQ-PR25 module was 17,33%. In the first assessment made according to the results obtained by questioning the genitourinarygastrointestinal symptoms related to the FM procedure both after the procedure and in the median 6.5th year,rectal bleeding was present in 2(4%),dysuria 3(6%),hematuria 5(11%) and frequency of urination in 5(11%) patients and in the second assessment,no new symptoms were added and the overall symptom rate decreased. In the first assessment,it was determined via NCI CTCAE-V 5.0 scale that the adverse effects of 9 patients (20%),who were identified with adverse effects,were grade 1 corresponding to mild side effects,and none of the patients experienced grade 2 or higher adverse events. In the second assessment,side effects were defined in 3 patients (7,5%) and grade 1 was mild. The ultrasound-guided FM implant procedure,which is used in prostate cancer radiotherapy is an easy,tolerable and safe technique that does not lead to adverse effects and loss of comfort in patients with long-term follow-u
